Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

F. Rabe, Klaus; J. Martinez, Fernando; T. Ferguson, Gary; Wang, Chen; Singh, Dave; A. Wedzicha, Jadwiga; Trivedi, Roopa; St. Rose, Earl; Ballal, Shaila; McLaren, Julie; Darken, Patrick; Aurivillius, Magnus; Reisner, Colin; Dorinsky, Paul

doi:10.1056/nejmoa1916046

Public

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

Published in New England Journal of Medicine • Jun 24, 2020

Authors:

Klaus F. Rabe

Fernando J. Martinez

Gary T. Ferguson

Abstract

BACKGROUND: -agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose levels of inhaled glucocorticoid, but studies at two dose levels are lacking. METHODS: In a 52-week, phase 3, randomized trial to evaluate the efficacy and safety of triple therapy at two do...

Subject

Glucocorticoid

COPD

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!